Interestingly, transitions had a higher percentage of co-occurring mutations compared to KRAS WT and transversions (Table 1).  As observed in EGFR-mutated NSCLC, co-mutation may have a negative prognostic role [27]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.